Evonik Industries AG (0QDS)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 21.21 |
|---|---|
| 52-week range | 12.49 – 21.82 |
| Return, 1 month / 3 months | +17.8% / +24.4% |
| Return, 1 year / 3 years | +51.5% / +57.6% |
| Trend | Uptrend |
| RSI (14) | 59 |
| Volatility (1 year) | 37.4% |
| Worst drawdown (1 year) | -16.4% |
| Average daily value traded | 7.01M EUR |
| Dividend yield | 4.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Evonik Industries is a specialty chemicals company based in Germany. It makes a broad range of chemical products and materials, including additives, specialty polymers, silica, hydrogen peroxide and amino acids for animal nutrition. Its customers are industrial firms in sectors such as automotive, coatings, plastics, consumer goods, health care and agriculture, and it also supplies feed and food ingredients. The company operates production sites and research facilities in many countries and serves manufacturers around the world.
On this site Evonik Industries AG appears as a stock on the London Exchange (UK), code 0QDS, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Evonik Industries AG (0QDS) trades on the London Exchange in UK. It last closed at EUR 21.21 on 23 October 2026.
Its price-based Market X-Ray is 77 out of 100 (a strong price profile), ranking 158 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 51.5% and over the last three months it rose 24.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 92 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 30.1% | ||
| From 52-week high | -1.2% | ||
| Momentum | 85 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 24.4% | ||
| 6-month return | 27.9% | ||
| 12-month return, skipping the last month | 28.6% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 37.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.4% | ||
| Liquidity | 71 · Strong | Trades actively. | |
| Average daily value traded | 7.01M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 57 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −1.2% |
|---|---|
| 1 month | +17.8% |
| 3 months | +24.4% |
| 6 months | +27.9% |
| 1 year | +51.5% |
| 3 years | +57.6% |
| 5 years | −0.0% |
Signals
| 50-day / 200-day average | 19.23 / 16.30 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.68 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 4 Jun 2026 | EUR 1.0000 |
| 29 May 2025 | EUR 1.1700 |
| 5 Jun 2024 | EUR 1.1700 |
| 1 Jun 2023 | EUR 1.1700 |
| 26 May 2022 | EUR 1.1700 |
| 3 Jun 2021 | EUR 1.1500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.